review model updat
db take weak organ sale product delay like keep share rang bound
investor day
yesterday follow announc result share close
versu close healthcar index
close thursday attribut weak share
primarili compani weaker-than-expect organ growth result
well delay percuv despit out-performance
neotract given stock valuat alreadi high expect
neotract franchis well perform core busi continu
rate share hold
weak organ growth quarter lead sale miss
organ growth quarter consist new product
contribut posit price volum declin
manag attribut top line miss two factor
first approxim half top-lin miss attribut weak
emea region relat lower-than-norm inventori build
distributor acquir part
compani go-to direct convers program relat vascular
solut acquisit overal go-to direct program
headwind compani expect shift tailwind
agre issu like one-tim natur would
expect merit convert direct sale model show
second despit strong season compani experienc weak
order volum north american distributor anesthesia
respiratori product manag view weak transitori
condent end-custom demand remain strong base distributor
trace report believ issu gave investor particular paus
given abnorm strong season gener strong util
environ broadli
manag provid initi full year guidanc sale growth expect
rang constant currenc basi
report basi organ growth expect rang
relat sale anniversari vascular
price feb usd
distribut gmt
deutsch bank seek busi compani cover research report thu investor
awar rm may conict interest could aect object report investor consid
report singl factor make invest decis disclosur analyst certif
solut neotract becom part core full year adjust
ep expect rang vs pre-result consensu
dbe manag reiter assumpt regard
neotract ep contribut expect neotract break-even
accret updat ep estim
ep estim ep estim
percuv system face coupl delay fals start
earn call manag note issu compani third
parti manufactur delay relaunch percurv
compani anticip would return market earli
earn call manag note compani need le
addit applic would delay reintroduct
market till purchas neotract percuv one
key futur revenu opportun compani potenti market
opportun million thu delay disappoint
new urolift indic expect contribut revenu
neotract receiv fda clearanc use urolift system men
benign prostat hyperplasia bph obstruct median lobe februari
call manag disclos plan spend major
invest sale train obstruct median lobe sale process
expect uptick urolift sale relat expand indic
manag expect neotract sale increas least
forecast ratio
full year growth larg driven
maintain long-term goal organ sale growth
organ growth compris new product
price volum vascular solut neotract
repres total constant currenc growth repres
organ growth expect
time new product increas benet overal
growth organ sale growth rate vari gener
rang except
takeawaysvari analysi surpris histori exceptp share compani data deutsch bank factsetsourc compani data deutsch bank factset product sale trend milrptdex-fxvascular north north north north million factset fs dbe estim sale report basi constant currenc basi y/i organ growth compris core volum new product price neotract contribut growth contribut ep y/i fs dbe due low tax rate addit detail quarter million except per share data chang sale constant currenc basi unless otherwis note posit sale growth constant currenc basi fx organ growth adj ep rang mix exceed projectect contribut million revenu overal growth miss consensu due weak north american volum emea distributor go-direct re-launch delay earli indic expans like impact sale quick view reduct acquisit vascular adj sg margin adj margin adj oper margin y/i relat gross margin flow tight control discretionari sg vascular solut adj tax rate y/i due tax adjust ep y/i well ahead fs dbe figur teleex abbrevi incom statement million except per share data
product categoryadjust incom statementtot profit op inc margin interest expens incom net incom average percent februari
